{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-031204","form_type":"8-K","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2026-06-30T12:30:20+00:00","discovered_at":"2026-06-30T12:35:02.322819+00:00","generated_at":"2026-06-30T12:35:12.167435+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"HCW Biologics regains Nasdaq bid price compliance; will effect 1-for-6 reverse split","bullets":["Nasdaq Panel confirmed compliance with Bid Price Rule; mandatory monitoring through June 17, 2027.","Company to effect 1-for-6 reverse stock split on June 30, 2026 to maintain compliance.","If non-compliant during monitoring, no additional cure period; may face delisting.","Company now compliant with all Nasdaq continued listing rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-031204","json":"https://secwatch.observer/filing/0001493152-26-031204.json","markdown":"https://secwatch.observer/filing/0001493152-26-031204.md","text":"https://secwatch.observer/filing/0001493152-26-031204.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000149315226031204/0001493152-26-031204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000149315226031204/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T12:35:12.167435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}